MX2023009249A - Método para prevenir, tratar o mejorar la colitis ulcerosa. - Google Patents
Método para prevenir, tratar o mejorar la colitis ulcerosa.Info
- Publication number
- MX2023009249A MX2023009249A MX2023009249A MX2023009249A MX2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A MX 2023009249 A MX2023009249 A MX 2023009249A
- Authority
- MX
- Mexico
- Prior art keywords
- amiselimod
- ulcerative colitis
- treating
- preventing
- ameliorating
- Prior art date
Links
- JVCPIJKPAKAIIP-UHFFFAOYSA-N 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol Chemical compound CCCCCCCOC1=CC=C(CCC(N)(CO)CO)C=C1C(F)(F)F JVCPIJKPAKAIIP-UHFFFAOYSA-N 0.000 title abstract 3
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 3
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 3
- 229950004817 amiselimod Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Luminescent Compositions (AREA)
- Cereal-Derived Products (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147060P | 2021-02-08 | 2021-02-08 | |
| PCT/EP2022/053030 WO2022167690A1 (en) | 2021-02-08 | 2022-02-08 | Amiselimod for preventing, treating, or ameliorating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009249A true MX2023009249A (es) | 2023-10-23 |
Family
ID=80447376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009249A MX2023009249A (es) | 2021-02-08 | 2022-02-08 | Método para prevenir, tratar o mejorar la colitis ulcerosa. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240299318A1 (https=) |
| EP (1) | EP4288041A1 (https=) |
| JP (1) | JP2024506041A (https=) |
| CN (1) | CN116940350A (https=) |
| AU (1) | AU2022217475A1 (https=) |
| CA (1) | CA3207440A1 (https=) |
| MX (1) | MX2023009249A (https=) |
| TW (1) | TW202245742A (https=) |
| WO (1) | WO2022167690A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025134072A1 (en) * | 2023-12-21 | 2025-06-26 | Bausch Health Ireland Limited | Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| BRPI0619894B8 (pt) | 2005-12-15 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | composto de amina e composição farmacêutica |
| JP5657565B2 (ja) | 2008-12-22 | 2015-01-21 | ノバルティス アーゲー | Ｓ１ｐ受容体アゴニストの投与レジメン |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| PL3242666T3 (pl) * | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| JP2018527406A (ja) * | 2015-08-11 | 2018-09-20 | アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ | Ｓ１ｐ受容体モジュレーターを含む組成物 |
| WO2020051568A1 (en) * | 2018-09-08 | 2020-03-12 | Wen Tan | NEW USE OF R-ENANTIOMER OF ADRENERGIC β2 RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ITS EXTRA INTESTINAL MANIFESTATIONS |
-
2022
- 2022-02-08 AU AU2022217475A patent/AU2022217475A1/en active Pending
- 2022-02-08 WO PCT/EP2022/053030 patent/WO2022167690A1/en not_active Ceased
- 2022-02-08 CN CN202280013674.8A patent/CN116940350A/zh active Pending
- 2022-02-08 CA CA3207440A patent/CA3207440A1/en active Pending
- 2022-02-08 MX MX2023009249A patent/MX2023009249A/es unknown
- 2022-02-08 EP EP22705759.3A patent/EP4288041A1/en active Pending
- 2022-02-08 JP JP2023547694A patent/JP2024506041A/ja active Pending
- 2022-02-08 US US18/276,120 patent/US20240299318A1/en active Pending
- 2022-02-08 TW TW111104482A patent/TW202245742A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4288041A1 (en) | 2023-12-13 |
| CN116940350A (zh) | 2023-10-24 |
| CA3207440A1 (en) | 2022-08-11 |
| TW202245742A (zh) | 2022-12-01 |
| JP2024506041A (ja) | 2024-02-08 |
| WO2022167690A1 (en) | 2022-08-11 |
| AU2022217475A1 (en) | 2023-08-24 |
| US20240299318A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MY202368A (en) | Methods of treating ulcerative colitis | |
| EP4414030A3 (en) | Treatment of fragile x syndrome with cannabidiol | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| PH12017500933A1 (en) | Sublingual administration of riluzole | |
| CR20200228A (es) | COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554) | |
| MX2022003193A (es) | Tratamiento de encefalopatia asociada al gen syngap1. | |
| PH12017500934A1 (en) | Sublingual formulation of riluzole | |
| MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| JOP20180110A1 (ar) | تركيبات وطرق لمعالجة أو الوقاية من اضطرابات متعلقة بأوكسالات | |
| MX2023006744A (es) | Compuestos antihelminticos que comprenden una estructura de tienopiridina. | |
| MY197209A (en) | Uses of benzimidazole derivative for nocturnal acid breakthrough | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| MX2023009249A (es) | Método para prevenir, tratar o mejorar la colitis ulcerosa. | |
| TW201613639A (en) | Methods for treating cardiovascular diseases | |
| MX394182B (es) | Proceso continuo para la preparacion de trazodona | |
| MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
| MX2018011379A (es) | Tratamiento del prurito uremico. | |
| ZA202108094B (en) | Mirikizumab for use in a method of treating crohn's disease | |
| AU2017245414A1 (en) | The cure for cancer | |
| MX2023001328A (es) | Compuestos de tiofeno para su uso en el tratamiento de la fibrosis renal. | |
| MY198500A (en) | Cancer treatment | |
| MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. |